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Phthalates are known endocrine disruptors and found in almost all people with several
associated adverse health outcomes reported in humans and animal models. Limited
data are available on the relationship between exposure to endocrine disrupting
chemicals and the human metabolome. We examined the relationship of metabolomic
profiles in plasma and urine of 115 pregnant women with eleven urine phthalate
metabolites measured at 26 weeks of gestation to identify potential biomarkers
and relevant pathways. Targeted metabolomics was performed by selected reaction
monitoring liquid chromatography and triple quadrupole mass spectrometry to measure
415 metabolites in plasma and 151 metabolites in urine samples. We have chosen
metabolites with the best defined peaks for more detailed analysis (138 in plasma and 40
in urine). Relationship between urine phthalate metabolites and concurrent metabolomic
markers in plasma and urine suggested potential involvement of diverse pathways
including lipid, steroid, and nucleic acid metabolism and enhanced inflammatory
response. Most of the correlations were positive for both urine and plasma, and further
confirmed by regression and PCA analysis. However, after the FDR adjustment for
multiple comparisons, only 9 urine associations remained statistically significant (q-values
0.0001–0.0451), including Nicotinamide mononucleotide, Cysteine T2, Cystine, and
L-Aspartic acid. Additionally, we found negative associations of maternal pre-pregnancy
body mass index (BMI) with more than 20 metabolomic markers related to lipid and
amino-acid metabolism and inflammation pathways in plasma (p = 0.01–0.0004), while
Mevalonic acid was positively associated (p = 0.009). Nicotinic acid, the only significant
metabolite in urine, had a positive association with maternal BMI (p= 0.002). In summary,
when evaluated in the context of metabolic pathways, the findings suggest enhanced
lipid biogenesis, inflammation and altered nucleic acid metabolism in association with
higher phthalate levels. These results provide new insights into the relationship between
phthalates, common in most human populations, and metabolomics, a novel approach
to exposure and health biomonitoring.
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INTRODUCTION
Environmental metabolomics, a newly emerging approach to
characterize the entirety of metabolites found in biological
specimens to obtain insight into the relationship with
expression, epigenetics, and various exposures, is attracting
increasing attention (1–3). Metabolomics is a complex dynamic
field of research that explores thousands of compounds in
different body fluids that are constantly changing due to
the influence of the environment, disease, life style factors and
microbiome (4). These scientific advancements aremade possible
by recent technological developments enabling comprehensive
simultaneous analysis of a large number of molecules in minute
volumes of biological specimens, permitting evaluation of
chemical modifications in the body that occur due to exposure
or in relation to health outcomes (5). A number of targeted
and untargeted approaches have been explored in this rapidly
developing field of research. However, for human population
studies focused on specific health outcomes or exposures,
targeted metabolomics that assesses hundreds rather than tens of
thousands of compounds may be more appropriate.
Mass spectrometry (MS) and nuclear magnetic resonance
(NMR) have emerged as the two popular analytic methodologies
for metabolomic research. NMR is often used for untargeted
studies where the main focus is profiling the entire complement
of metabolites in a sample often reaching tens of thousands of
compounds but sometimes with low sensitivity (6). MS is used
more commonly for targeted profiling when specific molecules
are characterized and the method can be optimized to minimize
interference with other metabolites (4, 7).
Phthalates are often added to industrial and consumer
products as solubilizing agents and to increase product flexibility
(8). Since they are not chemically linked to their substrates,
they have been found in household air, dust, and various foods
and drinks. Phthalates are ubiquitous in the environment and
recent biomonitoring studies indicate widespread exposure in
U.S. populations (9) and developing embryos can also be exposed
to phthalates. The majority of pregnant women were found to
have detectable phthalate concentrations in their urine (10). Early
life exposure to phthalates has been related to adverse health
outcomes in animals and humans, indicating a connection to the
fetal origins of disease (11–14).
Animal studies suggest that applyingmetabolomic approaches
to prenatal phthalate exposure may inform research on the
mechanisms linking developmental exposure to phthalates with
detrimental health effects in humans (15, 16). Experimental
results in rodents have shown a dose dependent relationship of
metabolomics markers with early life exposure to phthalates in a
sex specific manner (17–20).
To date, data on the relationship of phthalate exposure with
the human metabolome is limited. In a study of Chinese men
with phthalate exposure, elevated oxidative stress and fatty acid
oxidation, as well as changes to the urea cycle, tryptophan
and phenylalanine metabolism, were observed (21). Two other
studies have described metabolomic markers in pregnant women
using a targeted approach in relation to obesity (22) and preterm
birth (23), but they did not examine the metabolome in relation
to environmental toxicants in general or to endocrine disruptors
such as phthalates, specifically.
Previously, we characterized concentrations of eleven
phthalate metabolites in urine samples from pregnant women
(11). The focus of the current study is to explore the relationship
between metabolomic compounds found in plasma and urine
at the 26th week of gestation with concentrations of phthalate
urine metabolites measured at the same time, and to characterize
associations with maternal pre-pregnancy BMI.
MATERIALS AND METHODS
Maternal Demographics and Sample
Characteristics
Plasma and urine used for this study were randomly selected
convenience samples collected at 26.4 (±3.2; 20–36) weeks
gestation from pregnant women (N = 115) from the Center
for the Health Assessment of Mothers and Children of Salinas
(CHAMACOS) cohort (24). The subset included in this study
did not differ in demographic and exposure characteristics,
and it was representative of all pregnant women enrolled in
1999–2000. At the time of enrollment, CHAMACOS mothers
were at least 18 years of age, eligible for low income health
insurance, receiving prenatal care at one of several participating
clinics, and had experienced less than 20 weeks gestation. Urine
and plasma samples were aliquoted, barcoded, and stored in
−80◦C freezers at the UC Berkeley School of Public Health.
Samples were transferred to the Nomura Research Group on dry
ice and stored at −80◦C until targeted metabolomic analysis.
Women included in this study previously had their phthalate
exposure assessed based on concentrations of eleven urine
metabolites (12). CHAMACOS study protocols were approved by
the University of California, Berkeley Committee for Protection
of Human Subjects. All women provided written informed
consent at the time of enrollment.
Phthalate Metabolite Concentrations
Concentrations of eleven urine phthalate metabolites were
characterized by solid phase extraction coupled with isotope
dilution high-performance liquid chromatography-tandem
mass spectrometry (25), as previously described (11, 12). The
metabolites assessed included three LMW metabolites [MEP,
mono-n-butyl phthalate (MBP), mono-isobutyl phthalate
(MiBP)], four DEHP metabolites [mono(2-ethylhexyl) phthalate
(MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP),
mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-
5-carboxypentyl) phthalate (MECPP)], and four high molecular
weight (HMW) metabolites (monobenzyl phthalate (MBzP),
mono(3-carboxypropyl) phthalate (MCPP), monocarboxyoctyl
phthalate (MCOP), monocarboxynonyl phthalate (MCNP)].
In order to ensure quality control, laboratory and field blanks,
calibration standards, and spiked controls with low and high
concentrations were incorporated into the experimental runs.
Summary measurements of the LMW, HMW, and DEHP
metabolites in µg/L were generated by dividing the molar
concentrations of the metabolites by an average molecular
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weight for the group. Urinary phthalate concentrations were log
transformed and specific gravity adjusted for further analyses.
Metabolomic Profiling
Plasma and urine samples from the 115 women were analyzed
in duplicates. Urine samples were parallel aliquots (that did not
undergo previous freeze-thaw) of the same urines that were used
for the measurement of the concentrations of eleven phthalate
metabolites as noted above (11, 12).
The metabolomics profiles were assessed by selected reaction
monitoring liquid chromatography (LC) and triple quadrupole
mass spectrometry (MS). The QQQ LC-MS/MS targeted
method was chosen as it has been previously validated in
Nomura laboratory to measure the abundance of several
hundred representative polar and nonpolar metabolites (26). The
metabolites analyzed are found in functionally diverse metabolic
pathways. Of particular interest to us were pathways that are
likely to be affected by phthalate exposure, specifically those
induced by MEHP-mediated PPARγ activation, oxidative stress
and chronic inflammation pathways that play an important role
in mechanisms of obesity (27, 28).
Nonpolar lipid metabolites were extracted from 30 µL serum
or urine in 3ml of 2:1 chloroform: methanol and 1ml of
PBS with inclusion of internal standards C12 monoalkylglycerol
ether (MAGE) (10 nmol, Santa Cruz Biotechnology) and
pentadecanoic acid (10 nmol, Sigma-Aldrich). Organic and
aqueous layers were separated by centrifugation at 1000 × g for
5min and the organic layer was collected, dried under a stream
of N2 and dissolved in 120 µl chloroform. Polar metabolites
were extracted from 30 µL serum or urine in 160 µL of 1:1
(ACN:MeOH) with inclusion of internal standard D3N15 serine
(50 nM, Cambridge Isotope Laboratories, Inc., #DNLM-6863).
Urine specimens were vortexed, spun down at 21,000 × g
for 10min and the supernatant was used for experiments. All
samples were stored at −80◦C until analysis at which time they
were thawed, vortexed and placed in an auto-sampler for nomore
than 24 h prior to mass spec injection.
Metabolomic analysis was performed on an Agilent 6430 by
QQQ LC-MS/MS (Agilent Technologies, Santa Clara, California)
(29). The capillary voltage was set to 3.0 kV, and the fragmentor
voltage was set to 100V. The drying gas temperature was 350◦C
with a flow rate of 10.l/min, and the nebulizer pressure was
35 psi. Metabolites were identified by SRM of the transition
from precursor to product ions at associated optimized collision
energies and retention times as previously described (30).
Metabolomic markers were quantified by measuring the area
under the curve. Plasma nonpolar positive metabolites were
normalized to C12MAGE, plasma nonpolar negative metabolites
were normalized to Pentadecanoic acid, and all plasma polar
and urine metabolites were normalized to D3N15 Serine. Quality
assurance and control measures comprised laboratory and field
blanks, internal standards. Additionally, incorporated repeat
samples showed good reproducibility (CVs ≤ 3–15%).
Statistical Analysis
We first computed descriptive statistics for metabolites to
examine their distributions. Spearman correlation coefficients
were calculated to determine relationships between phthalate
metabolite concentrations and metabolomics profiles. Using
these correlation coefficients, we generated heat maps to show
the most prominent (r > 0.3) positive and negative associations
graphically.
We also generated regression models to assess the relationship
between concurrent prenatal phthalate levels and metabolomic
profiles in pregnant women, which were both log transformed.
Separate models were run for the plasma and urine metabolites.
In order to account for urinary dilution, plasma models
were examined in association with specific gravity adjusted
phthalate metabolite levels. Covariates in the plasma and
urine regressions included parity (binary; 0 or ≥1) and
maternal pre-pregnancy BMI (continuous), since these
variables were previously associated with urinary phthalate
metabolites in the CHAMACOS cohort (11). After observing
significant associations between phthalate metabolites and urine
metabolomic compounds, we ran similar regression models
using principal components derived from urine metabolomic
compounds as the outcome. 16 of the 40 total principal
components explained 95% of the variance and were included in
the analyses. Additionally, we used regression models to assess
the relationship between pre-pregnancy maternal body mass
index (BMI) and metabolomics compounds. Urinary metabolites
were adjusted for specific gravity (31).
All analyses were performed using STATA 12.0 (StataCorp,
College Station, TX) and R 3.3.0 (R Foundation for Statistical
Computing, Vienna, Austria) (32, 33).
Pathway Identification
Although correlation analysis used in this study treat the
metabolites as if they are independent variables, in fact they are
often related by a common metabolic pathway. Alternatively,
a single metabolite can participate in several pathways. We
used multiple online tools including MetaboAnalyst (34, 35)
(v3.0), Impala (36, 37) (v.9.0) and the KEGG Atlas of metabolic
pathways (38) to explore which metabolic pathways associated
with the metabolites found to have strong correlations to
phthalate levels in urine. Briefly, lists of metabolites with
significant associations with phthalate urine biomarkers and
prominent correlations (r > 0.3) were constructed and matched
to their Human Metabolome Data Base (HMDB) identifiers
using MetaboAnalyst (39). The online “Pathway Analysis”
tool in MetaboAnalyst allows for direct input of compound
names and generates the corresponding HMDB, PubChem,
and KEGG identifiers. Use of HMDB identifiers greatly
improved performance and reliability of the online tools by
eliminating any confusion due to metabolite synonyms. We
also manually searched for the HMDB identifier when it was
not automatically assigned by MetaboAnalyst. These HMDB
lists were submitted for pathway analysis, using “Pathway
overrepresentation analysis” for IMPALA with the following
parameters: “Homo Sapiens” pathway library, “Hypergeometric
Test,” “Relative-betweeness Centrality,” and “Used all compounds
in the selected pathways” as our options in MetaboAnalyst.
Finally, within the HMDB entry for most metabolites, a KEGG
link (38) provided detailed pathway diagrams.
Frontiers in Public Health | www.frontiersin.org 3 October 2018 | Volume 6 | Article 298
Zhou et al. Metabolomic Markers of Phthalate Exposure
RESULTS
Demographic and Exposure
Characteristics
Pregnant women in this study were young (25.6 ± 4.0 years
old) and many were overweight or obese (mean BMI 26.4
± 4.9 kg/m2) prior to pregnancy (Table 1). The distributions
of average gravity-adjusted phthalate metabolite concentrations
during pregnancy for the subset of the CHAMACOS mothers
included in this study are similar to the levels observed in the full
cohort (11, 12). Detection frequencies of phthalate metabolites
during pregnancy were 90–100%. MEP had the highest
urinary concentrations during pregnancy. Other common urine
metabolites included MBP, MEHHP, and MECPP. The exposure
in CHAMACOS pregnant women were comparable to trends
seen in the general U.S. population (11).
Urine and Plasma Metabolome
Among the 415 metabolic compounds targeted by our
metabolomics platform, multiple lipid species were assessed
including fatty acids, acylglycerophospholipids, neutral lipids,
ether lipids, eicosanoids, sterols, and sphingolipids as well as
polar metabolites that encompass major metabolic pathways
TABLE 1 | Characteristics and phthalate metabolite concentrations for
CHAMACOS mothers (N = 115).
Characteristics Mean ± SD Median Min-Max
Age, years 25.6 ± 4.0 25 18–37
BMI (kg/m²) 26.4 ± 4.9 25.1 17.7–45.5
PHTHALATE METABOLITE CONCENTRATIONS (ng/mL)
LMW
MEP 347.4 ± 623.0 161.1 0.9–5004
MBP 42.8 ± 69.2 25.9 1.8–597.1
MiBP 5.1 ± 6.1 3.0 0.1–37.4
LMW Sum 426.8 ± 690.5 209.6 13.3–5536.9
DEHP
MEHP 6.5 ± 11.1 3.9 ND-94.2
MEHHP 31.1 ± 80.5 17.1 2–781.2
MEOHP 23.8 ± 60.4 13.8 0.2–588
MECPP 51.9 ± 120.5 27.4 5.8–1102.8
DEHP Sum 111.1 ± 264.4 63.3 9.1–2516.9
HMW
MBzP 11.5 ± 13.0 7.2 ND-90.7
MCPP 2.4 ± 1.8 1.9 ND-9.6
MCOP 3.8 ± 2.9 3.2 ND-22.4
MCNP 2.3 ± 1.7 2.0 ND-10.2
HMW Sum 132.2 ± 266.6 83.1 14-2533.6
All measures were specific gravity adjusted.
ND, Non-Detected; MEP, monoethyl phthalate; MBP, mono-n-butyl phthalate; MiBP,
mono-isobutyl phthalate; LMW, low molecular weight metabolites; MEHP, mono(2-
ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-
ethyl-5-oxohexyl) phthalate; MECPP, mono(2- ethyl-5-carboxypentyl) phthalate; DEHP,
di-2-ethylhexyl phthalate; MBzP, monobenzyl phthalate; MCPP, mono(3- carboxypropyl)
phthalate; MCOP, monocarboxyoctyl phthalate; MCNP, monocarboxynonyl phthalate;
HMW, high molecular weight metabolites; BMI, body mass index.
such as glycolysis, TCA cycle, amino acid, pentose phosphate,
hexosamine, polyamine, nucleotide, glycan, glucuronate, and
inositol metabolism.We characterized 264 non-polar metabolites
in plasma, as well as 151 polar metabolites in both plasma and
urine samples. Detailed information on the assessed metabolites
in plasma and urine is presented in Supplemental Table 1.
Peak analysis was performed on high quality and consistent
spectrographic peaks (Figure 1) which resulted in 138 plasma
and 40 urine metabolites to be included for further analysis.
Examples of distributions of several metabolic markers in
plasma are shown in Figure 2. Free Fatty Acid (C16:0 FFA)
is frequently related to inflammation and involved in lipid
biosynthesis, high relative abundances of this metabolite were
found in fewer than half of the samples (Figure 2A). For estradiol
hormone, less abundance was observed overall but with a more
normal distribution (Figure 2B). In contrast, adenine (reflecting
nucleic acid degradation) was found in greater abundance across
participant samples. We expected the relative abundance to be
different in plasma and urine. Indeed, ribose 1,5-bisphosphate
(R15BP) was the only metabolite that had the abundance
appreciably correlated in both tissues (r = 0.33).
Association of Phthalate Exposure and
Metabolic Profiles in Pregnant Women
In plasma, several free fatty acids, hormones, lysolipids, ceramide
and triacylglycerol metabolites were correlated with MEB
and LMW Sum urine levels (Figure 3A). We also conducted
regression analysis, and many metabolites (N = 72) were
significantly associated with phthalates including 23.6% (N = 17)
with MEP, confirming observations with correlation analysis
(Supplemental Table 2). Most of the associations were positive,
with p-values ranging from 0.0002 to 0.049, and for 15
metabolites that were negatively associated, p-values ranged
from −0.0003 to −0.048. All positive and negative betas
were relatively small (−0.321 to 0.478). Further, we conducted
sensitivity analysis adjusting for maternal BMI and parity, two
variables that were previously identified as the most relevant
to phthalate metabolite levels (11). The results were almost
identical to non-adjusted regression model. However, when
we did adjustment for multiple comparisons (FDR) significant
findings were attenuated.
In urine, N-acetylneuraminic acid (Neu5AC), amino acids,
nicotinic acid metabolites, adenine and thymine were correlated
with many phthalate metabolite concentrations including
MBP, MiBP, MBzP, and MCOP (Figure 3B). Regression
analysis confirmed that there were 171 significant associations,
with multiples for different phthalate urine biomarkers
(Supplemental Table 3). Moreover, even after FDR correction,
9 positive associations remain significant (q-values ranging
from 0.0001 and 0.0451) in the model adjusted for BMI and
parity. For instance, nicotinamide mononucleotide (NMN) was
associated withMiBP (beta= 0.452), MBP (beta= 0.433), MBzP
(beta= 0.380), MCPP (beta= 0.472), and MCNP (beta= 0.481).
Cystine and cysteineT2 were associated with MiBP (betas 0.282
and 0.319, respectively) and cysteine was also associated with
MCPP (beta = 0.341). L-Aspartic acid association with MiBP
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FIGURE 1 | Examples of the metabolomic compounds considered to be
acceptable for analysis that had peaks either clearly defined (A) or sufficiently
defined (B). Spectrograms similar to the example (C) were excluded.
also remained significant after FDR adjustment (beta = 0.338,
q= 0.0195).
In the PCA analysis, 16 of the 40 PCs explained 95% of
the variance, and were included in the regression analysis with
phthalate metabolite concentrations. After FDR adjustment, only
PC1 that explained ∼50% of the variance was significantly
associated with urinary phthalate metabolites (MBzP in the crude
and adjusted for BMI and parity models and MCPP in the crude
model). There was no clear clustering bymetabolite (values of the
PC loadings ranged from−0.24 to−0.05).
Metabolomic Markers and Obesity in
CHAMACOS Women
Women in the CHAMACOS cohort had a high prevalence of
obesity before pregnancy (>50% were overweight or obese),
FIGURE 2 | Distribution of representative metabolomic markers:
(A) Inflammation and Lipid Biosynthesis, (B) Hormones, (C) Nucleotide
Metabolism. The x-axis shows the relative abundance of the metabolite and
the y-axis—the number of pregnant women.
with their BMI ranging broadly from 17.7 to 45.5 (Table 1). We
explored the relationship of the pre-pregnancy BMI with targeted
metabolomics markers characterized in this study to establish
their biological relevance. A complete list of the associations
is presented in Supplemental Table 4. Most of the coefficients
for metabolomic compounds in plasma, among 25 that
were statistically significant, were negative. These compounds
included glycine (beta = −1.92; p = 0.0004); acetylcarnitine
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FIGURE 3 | Spearman correlation matrix between concentrations of eleven urine phthalate metabolites and metabolomic markers in plasma (A) and urine (B).
FIGURE 4 | Flowchart depicting our approach to identify which metabolic pathways are influenced by phthalate exposure in pregnant women.
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(beta = −1.69; p = 0.002); isoleucine (beta = −1.93; p = 0.01);
cholesterol (beta = −3.04; p = 0.01); tryptophan (beta = −3.24;
p = 0.02). Mevalonic acid had a strong positive association
with BMI (beta = 9.58.24; p = 0.009). In contrast, nicotinic
acid was the only urine metabolomic compound that has shown
a statistically significant association with BMI (beta = 4.01,
p= 0.002).
Metabolic Pathways Associated With
Phthalate Exposure
Our approach to identifying which metabolic pathways are
influenced by phthalate exposure is depicted in Figure 4. As
shown in Figure 5, lipid biosynthetic and degradation products
and arachidonate containing lipids were correlated with
phthalate exposure markers (urine phthalate metabolite
concentrations). Metabolites reflecting components of
the biological membrane, phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylserine (PS),
and phosphatidylinositol (PI), cholesterol and sphingomyelin
were also correlated with phthalate exposure, most notably
MEP, MBP, MiBP, and LMW Sum levels in urine (Figure 5A).
Multiple triacylglyceride (TAG) species were associated with
many phthalate metabolites measured in urine (Figure 5A).
TAGs serve as a reservoir for energy storage in the form of
esterified fatty acids, existing as lipid droplets found abundantly
in adipose tissue. Palmitoyl carnitine (16:0 AC) and steroyl
carnitine (18:0 AC), conjugated forms of FFAs involved in beta-
oxidation, also correlate with previously measured phthalate
urine metabolite concentrations (Figure 5A). Metabolic
products formed from phospholipid and TAG phospholipase
mediated degradation, including lysophosphatylcholine (LPC),
lysophosphatidylethanolamine (LPE), lysophosphatidate
(LPA), lysophosphatidylserine (LPS), diacylglycerides (DAGs),
monoacylglycerides (MAGs), and FAA were associated with
phthalate urine levels (Figure 5B). Ceramide, ceramide-
1phosphate, sphingosine and sphingosine 1-phosphate,
metabolites that are intermediates of sphingosine biosynthesis
and members of an inflammatory signaling pathway, also appear
to be associated with the phthalate exposure (Figure 5C). The
same was observed for a subset of phospholipids, PI and PS and
TAGs containing arachidonate (20:4). Similarly, arachidonate,
the free fatty acid (FFA) precursor for eicosanoid biosynthesis
also demonstrated noticeable relationship with phthalate
exposure markers including MEP, MBP, MiBP, LMW Sum,
MEHP, MEHHP, MECHP, MECPP, DEHP Sum, and HMW Sum
(Figure 5C).
Plasma Hormone Metabolites
Several hormones that are known to influence metabolism
correlate with phthalate exposure markers in CHAMACOS
pregnant women. The androgen metabolites dihydrotestosterone
(DHT) and dehydroepiandrosterone (DHEA) were associated
with many of the detected phthalate metabolites (Figure 6).
In addition, MEP and the sum of LMW phthalate metabolite
concentrations appear to be aligned with many steroid hormones
including cortisol, a stress hormone, estradiol and testosterone,
FIGURE 5 | Plasma metabolites correlated with phthalate exposure likely reflect enhanced lipid biosynthesis (A), arachidonate enrichment and release (B), and
inflammatory signaling (C).
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hormones that regulate sex development, and pregnenolone- and
estradiol-sulfate hormones.
Plasma and Urinary Nucleic Acid
Degradation Products
Phthalate exposure markers as measured by concentration
of 11 urine metabolites were associated with several nucleic
acid degradation products including pyrimidine metabolites,
thymine, uridine and ureidopropionate, and purine metabolites
FIGURE 6 | Hormone metabolites correlate with phthalate exposure. Red
arrows indicate upregulation of corresponding metabolite.
AMP, IMP, hypoxanthine, and xanthine (Figure 7). The
correlations ranging r = 0.31–0.46 are observed with most
phthalate urine levels including MBP, MiBP, MEHP, MEHHP,
MEOHP, MECPP, DEHP Sum, MBzP, MCPP, MCOP, and HMW
Sum. The accumulation of nucleic acid degradation products
suggests an increased nucleic acid turnover and/or impaired
salvage with phthalate exposure. Oxidative stress may also be
exacerbated with phthalate exposure. Hydrogen peroxide is
concomitantly generated with the conversion of hypoxanthine to
xanthine by xanthine oxidase.
DISCUSSION
We determined metabolomic profiles in plasma and urine
from pregnant women and examined their association with
phthalate urine biomarkers during gestation and pre-pregnancy
obesity. We observed mostly positive associations with higher
phthalate concentrations which could be suggestive of increased
inflammation, changes in lipid biosynthesis as well as hormone
and nucleic acid metabolism with higher urine phthalate levels,
providing additional insight into the underpinnings of how
phthalates may contribute to obesity and other health outcomes
(40).We also demonstrated significant negative relationship of
over 20 of metabolomics compounds in plasma with maternal
pre-pregnancy BMI. This finding is consistent with other studies
that reported that women’s obesity before pregnancy is related to
their metabolic status (22).
In our study, womenwith higher phthalate exposure tended to
have enriched arachidonate content in lipids (Figure 5), a change
that perhaps enhances the inflammatory response in much the
same way a high n-6:n-3 fatty acid ratio from a Western diet
contributes to inflammation (41). Arachidonate is the precursor
for eicosanoid biosynthesis (42), and release of arachidonate from
complex lipids is achieved through the action of phospholipases
FIGURE 7 | Nucleic acid degradation products correlate with phthalate exposure in plasma and urine. Red arrows indicate upregulation, and green arrows indicate
downregulation of corresponding metabolite.
Frontiers in Public Health | www.frontiersin.org 8 October 2018 | Volume 6 | Article 298
Zhou et al. Metabolomic Markers of Phthalate Exposure
which generate lipid degradation products, the same ones which
also correlate with phthalate exposure. In animal models, the
association of phthalate biomarkers with increased inflammatory
response has been clearly demonstrated with detrimental effects
on the neonate (43–45). For example, as with our study,
rats exposed to phthalate also have increased arachidonate
containing phosphatidylcholine (46). Multiple studies have
evaluated phthalate exposure in pregnant women (47–49), and
several have also demonstrated relationships with oxidative
stress markers across pregnancy (11, 50). Our results suggest
that enhanced inflammatory response from phthalate exposure
is linked to a biological feature further upstream, namely
the arachidonate availability, storage and release to propagate
eicosanoid biosynthesis. These cellular events are supported by
the correlation of several lipid degradation products, DAGs,
MAGs, lysolipids, and arachidonate (Figure 5B).
Most lipid metabolites that correlate with phthalate exposure
have a positive association suggesting that phthalates may have a
mechanistic relationship with the up-regulation of lipid synthesis
pathways or down-regulation of lipid degradation pathways. In
contrast, one of the negatively associated lipid metabolites, 20:4
LPS (Figure 3A), a degradation product of phosphatidylserine
may indicate a compensatory role with phthalate exposure,
regulating lipid redistribution and inflammation similar to
shown in animal studies (51, 52).
Our results also recapitulate a mechanistic model which may
explain how phthalate exposure induces lipid biosynthesis and
weight gain. The correlation of biosynthetic lipids with phthalate
exposure is consistent with previous findings (53–55). For
example, recent experiments identified multiple genes associated
with lipid metabolism that are up-regulated with phthalate
exposure in rat embryo and human fetal gonad cultures, such
as liver-X-receptor alpha (LXRα), sterol regulatory element-
binding protein (SREBP) 1c, and SREBP2 (53-55). Muczynski
et al., showed that phthalates increase the levels of mRNA for
LXRα, and SREBP members, possibly up-regulating lipid and
cholesterol synthesis in human fetal gonads (53). Consistent
with the up-regulated genes, phospholipids and neutral lipids
are increased in rats with phthalate exposure (46). Our results
showing correlations between higher phthalate exposure with
products of lipid biosynthesis provides evidence that phthalate-
induced disruption of upstream transcription factors (LXR,
SREBP1c, SREBP2) may also occur in humans, contributing
to increased lipid biosynthesis and obesity. In addition,
several correlating sphingolipids such as ceramide, ceramide-1-
phosphate, sphingosine, and sphingosine-1-phosphate may serve
as signaling molecules that influence obesity, diabetes, metabolic
syndrome (56–58), oxidative stress and inflammatory signaling
(59). Previous reports describe the effects of phthalates on
sphingolipid metabolism in rat brain linked with hippocampal
development (60) and liver toxicity (61), but additional research
is required to understand their role in maternal-neonate health
and obesity.
Characteristics of four metabolomic compounds (cysteine
T2, cystine, NMN and L-aspartic acid) that showed strong
associations with phthalate metabolite concentrations in urine in
our study (they remained statistically significant after multiple
comparison adjustment), also support the involvement with
these metabolic pathways. For instance, cysteine has many
biological functions, including antioxidation (62). Aside from its
oxidation to cystine (oxidized dimeric form of cysteine), cysteine
participates in numerous posttranslational modifications. The
nucleophilic sulfhydryl group allows cysteine to conjugate to
other groups. Cystine is found in high concentrations in digestive
enzymes and in the cells of the immune system and connective
tissues. Cystinuria is an inherited disorder of the transport of
cystine resulting in an excess of cysteine in the urine and the
formation of cystine stones (63). Nicotinamide Mononucleotide,
NMN, a key NAD+Intermediate was shown to be effective in
treating diet and age-induced diabetes in mice (64). NMN also
enhances hepatic insulin sensitivity and restores gene expression
related to oxidative stress, inflammatory response, and circadian
rhythm. L-aspartic acid is an α-amino acid that is used in the
biosynthesis of proteins, and participates in the urea cycle (65).
Our observations of metabolomic profiles in pregnant women
are consistent with findings by Zhang et al. in phthalate exposed
men (21). First, while prostaglandin metabolites were increased
in these male subjects, we observed that upstream metabolites
to eicosanoid biosynthesis were correlated with phthalate
exposure- namely arachidonate and arachodonate-containing
lipids in plasma of pregnant women in our study. Second, the
associations we observed between phthalate exposure biomarkers
and acylcarnitines is consistent with increases in male urine
and female plasma with higher phthalate exposure, suggesting
that mitochondrial function may be influenced by phthalate
exposure. Further experiments are necessary to determine
whether acylcarnitines are increased because beta-oxidation is
up-regulated as concluded by Zhang et al., or if it may be a
result of mitochondrial dysfunction (66). Third, urinary Neu5AC
and N-acetylmannosamine may indicate protein glycosylation
impairment (67, 68) causing the aminoglycans to accumulate in
urine with phthalate exposure. Last, several urinary amino acids
were elevated inmen and womenwith higher phthalate exposure,
including cystine (Figure 3B), alanine and tryptophan (data not
shown), a potential sign of disrupted amino acid metabolism.
Another intriguing finding from our analysis is the prominent
positive correlation of steroid hormones and sulfated hormones
with phthalate exposure biomarkers. Steroid signaling is
considered to be critical for organizing embryonic development
(69). Furthermore, maternal steroid sulfonation is a common
metabolic pathway during embryonic development in many
vertebrates (70). Our results suggest that phthalates have the
potential to disrupt the close hormonal communication between
the developing placenta and fetus. Phthalates are suspected
endocrine disruptors, but their precise relationship with sex
steroid hormone levels is not sufficiently understood. Although
genes related to steroid metabolism are up-regulated in phthalate
exposed rats (54), prenatal exposure is associated with lower
circulating testosterone and aldosterone levels in adult male
offspring and estradiol in the female (71). Additionally, as
it was shown in zebrafish and in human adrenal cell line,
testosterone may be decreased with phthalate exposure (72). In
contrast, our results show that pregnant women with higher
levels of phthalates tend to have increased steroid hormone
Frontiers in Public Health | www.frontiersin.org 9 October 2018 | Volume 6 | Article 298
Zhou et al. Metabolomic Markers of Phthalate Exposure
levels. It may be possible that these hormone levels are
related to cholesterol availability which is regulated by SREBP1c
and activated by phthalate exposure (55). The discrepancy in
hormone level changes in previous reports and our findings
may reflect experimental differences in animal or cell culture
models compared to human subjects, or perhaps related to dose
effects (46).
Our pathway analysis also suggests a novel relationship
with nucleic acid metabolism, an association in line with our
previous report linking phthalate exposure and differential DNA
methylation in the same cohort (12, 73, 74). The correlation
of several nucleotides and nucleosides in plasma and urine
with higher exposures suggests that phthalates may influence
degradation, salvage, and elimination pathways of nucleic acid
metabolism. Purines, hypoxanthine and xanthine data suggest
activation of purine degradation by xanthine oxidase which also
produces hydrogen peroxide, a potential source of oxidative
stress (75–78). Additional research is needed to establish whether
the alterations of nucleic acid metabolites reflect enhanced DNA
repair mechanism to combat phthalate induced injury (79).
Our study has several strengths and some limitations. It
was conducted in a relatively homogeneous Mexican-American
cohort of pregnant women, potentially reducing the impact
of unaccounted confounding (80). The women had levels of
phthalate exposure typical for many American cohorts; thus,
making the findings regarding their metabolomic profile fairly
generalizable. While this study is comparable in size with
other published metabolomics studies, confirmation in larger
diverse cohorts will be required in the future. We employed
a targeted metabolomics analysis with more than a hundred
measured metabolites across two sample types which provided
an opportunity to ascertain the relationship between phthalate
urine metabolite concentrations with the urine and plasma
metabolomes. Our study of pregnant women is only the first
step to explore the environmental metabolomics in this cohort
with extensive exposure data for pesticides, flame retardants
and other chemicals measured during pregnancy and in their
children, whom we have followed through age 18 years to date.
In the future, pending additional funding, we plan to expand
the number of participants, characterize their metabolome at
multiple time-points and explore the relationship of identified
metabolomics markers with health outcomes such as obesity,
hormonal, and reproductive outcomes in children that may be
affected by early life phthalate exposure.
In conclusion, this study for the first time characterized
the metabolome of urine and plasma in pregnant women
and explored their relationships with urine phthalate
concentrations measured by standard methodologies as a
biomarker of phthalate exposure. We identified new candidate
metabolomic markers associated with phthalates that in
the future can be explored in relation to various health
outcomes. Pathway analysis indicates potential alterations in
lipid biogenesis, inflammation, sphingolipid signaling and
nucleotide degradation which could exacerbate oxidative
stress. These results provide new insights into the relationship
between phthalate exposure and metabolomic profiles during
gestation.
AUTHOR CONTRIBUTIONS
KH advised MZ in the initial statistical analyses and planning of
the experiments. MZ, BF, and VT prepared samples, conducted
experiments, and contributed to the data analysis. NH designed
the study and worked on the paper with MZ and GT. DL
conducted pathway analysis and helped with the writing of
the manuscript. RG and GT were involved in the statistical
analyses. BE, AB, DN contributed to the data interpretation and
preparation of the manuscript.
ACKNOWLEDGMENTS
This project was supported by R01 ES021369, P01 ES009605,
R24ES028529, RC2 ES018792, UG3OD023356, F31 ES027751
from NIEHS and RD83451301, R82670901, RF83171001 from
EPA. We are grateful to the CERCH, Children’s Environmental
Health laboratory and CHAMACOS field staff and participants
for their contributions. Dr. Calafat’s assistance with the exposure
assessment is sincerely appreciated.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fpubh.
2018.00298/full#supplementary-material
REFERENCES
1. Wild CW. The exposome:from concept to utility. Int J Epidemiol. (2012)
41:24–32. doi: 10.1093/ije/dyr236
2. Rappaport S, Smith M. Environment and disease risks. Science (2010)
330:460–1. doi: 10.1126/science.1192603
3. Holland N. Future of environmental research in the age of
epigenomics and exposomics. Rev Environ Health (2016) 32:45–54.
doi: 10.1515/reveh-2016-0032
4. Bjerrum JT. Metabonomics: analytical techniques and associated
chemometrics at a glance. In: Bjerrum JT, editor.Metabonomics: Methods and
Protocols. New York, NY: Springer (2015). p. 1–14.
5. Fearnley L, Inouye M. Metabolomics in epidemiology: from metabolite
concentrations to integrative reaction networks. Int J Epidemiol. (2016)
45:1319–28. doi: 10.1093/ije/dyw046
6. Abbassi-Ghadi N, Kumar S, Huang J, Goldin R, Takats Z, Hanna GB.
Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J
Cancer (2013) 49:3625–37. doi: 10.1016/j.ejca.2013.07.004
7. Abdel Rahman AM, Pawling J, Ryczko M, Caudy AA, Dennis JW.
Targeted metabolomics in cultured cells and tissues by mass spectrometry:
method development and validation. Anal Chim Acta (2014) 845:53–61.
doi: 10.1016/j.aca.2014.06.012
8. Ellero-Simatos S, Claus SP, Benelli C, Forest C, Letourneur F, Cagnard
N, et al. Combined transcriptomic-(1)H NMR metabonomic study
Frontiers in Public Health | www.frontiersin.org 10 October 2018 | Volume 6 | Article 298
Zhou et al. Metabolomic Markers of Phthalate Exposure
reveals that monoethylhexyl phthalate stimulates adipogenesis and
glyceroneogenesis in human adipocytes. J Proteome Res. (2011) 10:5493–502.
doi: 10.1021/pr200765v
9. Centers for Disease Control. Fourth National Report on Human Exposure to
Environmental Chemicals, Centers for Disease Control (2009).
10. Woodruff T, Zota A, Schwartz J. Environmental chemicals in pregnant women
in the United States: NHANES 2003-2004. Environ Health Perspect. (2003)
119:878–85. doi: 10.1289/ehp.1002727
11. Holland N, Huen K, Tran V, Street K, Nguyen B, Bradman A, et al. Urinary
phthalate metabolites and biomarkers of oxidative stress in a Mexican-
American cohort: variability in early and late pregnancy. Toxics (2016) 4:7.
doi: 10.3390/toxics4010007
12. Huen K, Calafat AM, Bradman A, Yousefi P, Eskenazi B, Holland N. Maternal
phthalate exposure during pregnancy is associated with DNA methylation of
LINE-1 and Alu repetitive elements in Mexican-American children. Environ
Res. (2016) 148:55–62. doi: 10.1016/j.envres.2016.03.025
13. Silva M, Samandar E, Preau JJ, Reidy J, Needham L, Calafat A. Quantification
of 22 phthalate metabolites in human urine. J Chromatogr B Analyt
Technol Biomed Life Sci. (2007) 860:106–12. doi: 10.1016/j.jchromb.2007.
10.023
14. Zota AR, Calafat AM, Woodruff TJ. Temporal trends in phthalate
exposures: findings from the National Health and Nutrition Examination
Survey, 2001–2010. Environmental Health Perspectives (2014) 122:235–41.
doi: 10.1289/ehp.1306681
15. Houten SM, Chen J, Belpoggi F, Manservisi F, Sanchez-Guijo A, Wudy
SA, et al. Changes in the metabolome in response to low-dose exposure
to environmental chemicals used in personal care products during
different windows of susceptibility. PLoS ONE (2016) 11:e0159919.
doi: 10.1371/journal.pone.0159919
16. Hsu JY, Shih CL, Liao PC. Exposure marker discovery of phthalates
using mass spectrometry. Mass Spectrom. (2017) 6(Spec Iss):S0062.
doi: 10.5702/massspectrometry.S0062
17. Banerjee R, Pathmasiri W, Snyder R, McRitchie S, Sumner S. Metabolomics
of brain and reproductive organs: characterizing the impact of gestational
exposure to butylbenzyl phthalate on dams and resultant offspring.
Metabolomics (2012) 8:1012–25. doi: 10.1007/s11306-011-0396-y
18. van Ravenzwaay B, Coelho-Palermo Cunha G, Strauss V, Wiemer J,
Leibold E, Kamp H, et al. The individual and combined metabolite
profiles (metabolomics) of dibutylphthalate and di(2-ethylhexyl)phthalate
following a 28-day dietary exposure in rats. Toxicol Lett. (2010) 198:159–70.
doi: 10.1016/j.toxlet.2010.06.009
19. Zhang J, Yan L, Tian M, Huang Q, Peng S, Dong S, et al. The metabonomics
of combined dietary exposure to phthalates and polychlorinated biphenyls in
mice. J Pharm Biomed Anal. (2012) 66:287–97. doi: 10.1016/j.jpba.2012.03.045
20. Sumner S, Snyder R, Burgess J, Myers C, Tyl R, Sloan C, et al. Metabolomics
in the assessment of chemical-induced reproductive and developmental
outcomes using non-invasive biological fluids: application to the study of
butylbenzyl phthalate. J Appl Toxicol. (2009) 29:703–14. doi: 10.1002/jat.1462
21. Zhang J, Liu L, Wang X, Huang Q, Tian M, Shen H. Low-level
environmental phthalate exposure associates with urine metabolome
alteration in a Chinese male cohort. Environ Sci Technol. (2016) 50:5953–60.
doi: 10.1021/acs.est.6b00034
22. Hellmuth C, Lindsay K, Uhl O, Buss C, Wadhwa P, Koletzko B, et al.
Association of maternal prepregnancy BMI with metabolomic profile across
gestation. Int J Obes. (2016) 41:159–69. doi: 10.1038/ijo.2016.153
23. Cecatti J, Souza R, Sulek K, Costa M, Kenny L, McCowan L, et al. Use
of metabolomics for the identification and validation of clinical biomarkers
for preterm birth: Preterm SAMBA. BMC Pregn Childbirth (2016). 16:212.
doi: 10.1186/s12884-016-1006-9
24. Eskenazi B, Bradman A, Gladstone E, Jaramillo S, Birch K, Holland N.
CHAMACOS, a longitudinal birth cohort study: lessons from the fields. J
Childrens Health (2003) 1:3–27. doi: 10.3109/713610244
25. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. Urinary
levels of seven phthalate metabolites in the U.S. population from the National
Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ
Health Perspect. (2004) 112:331–8. doi: 10.1289/ehp.6723
26. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the
omics trilogy. Nat Rev Mol Cell Biol. (2012) 13:263–9. doi: 10.1038/nrm3314
27. Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, et al.
The endocrine disruptor monoethyl-hexyl-phthalate is a selective
peroxisome proliferator-activated receptor gamma modulator that
promotes adipogenesis. J Biol Chem. (2007) 282:19152–66. doi: 10.1074/
jbc.M702724200
28. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse
biology of PPARgamma. Annu Rev Biochem. (2008) 77:289–312.
doi: 10.1146/annurev.biochem.77.061307.091829
29. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, et al.
Ether lipid generating enzyme AGPS alters the balance of structural and
signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci USA (2013)
110:14912–7. doi: 10.1073/pnas.1310894110
30. Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman
TR, et al. GSTP1 is a driver of triple-negative breast cancer cell
metabolism and pathogenicity. Cell Chem Biol. (2016) 23:567–78.
doi: 10.1016/j.chembiol.2016.03.017
31. Sauvé JF, Lévesque M, Huard M, Drolet D, Lavoué J, Tardif R, et al.
Creatinine and specific gravity normalization in biological monitoring
of occupational exposures. J Occup Environ Hyg. (2015) 12:123–9.
doi: 10.1080/15459624.2014.955179
32. StataCorp. Stata Statistical Software: Release 12. College Station, TX: Statacorp
LP (2011).
33. Team RDC. R: A Language and Environment for Statistical Computing.
Vienna: R Foundation for Statistical Computing (2008).
34. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server
for metabolomic data analysis and interpretation. Nucleic Acids Res. (2009)
37:W652–60. doi: 10.1093/nar/gkp356
35. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst
2.0—a comprehensive server for metabolomic data analysis.Nucleic Acids Res.
(2012) 40:W127–33. doi: 10.1093/nar/gks374
36. Kamburov A, Cavill R, Ebbels TM, Herwig R, Keun HC. Integrated pathway-
level analysis of transcriptomics and metabolomics data with IMPaLA.
Bioinformatics (2011) 27:2917–8. doi: 10.1093/bioinformatics/btr499
37. Cavill R, Kamburov A, Ellis JK, Athersuch TJ, Blagrove MS, Herwig R,
et al. Consensus-phenotype integration of transcriptomic and metabolomic
data implies a role for metabolism in the chemosensitivity of tumour
cells. PLoS Comput Biol. (2011) 7:e1001113. doi: 10.1371/journal.pcbi.10
01113
38. Okuda S, Yamada T, Hamajima M, Itoh M, Katayama T, Bork P, et al. KEGG
Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res.
(2008) 36:W423–6. doi: 10.1093/nar/gkn282
39. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst
4.0: towards more transparent and integrative metabolomics analysis. Nucleic
Acids Res. (2018) 46:W486–94. doi: 10.1093/nar/gky310
40. Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates:
a link to the obesity epidemic? Mol Cell Endocrinol. (2009) 304:43–8.
doi: 10.1016/j.mce.2009.02.017
41. Simopoulos AP. The importance of the ratio of omega-6/omega-
3 essential fatty acids. Biomed Pharmacother. (2002) 56:365–79.
doi: 10.1016/S0753-3322(02)00253-6
42. Harizi H, Corcuff J-B, Gualde N. Arachidonic-acid-derived eicosanoids:
roles in biology and immunopathology. Trends Mol Med. 14:461–9.
doi: 10.1016/j.molmed.2008.08.005
43. Shin IS, Lee MY, Cho ES, Choi EY, Son HY, Lee KY. Effects of
maternal exposure to di(2-ethylhexyl)phthalate (DEHP) during pregnancy on
susceptibility to neonatal asthma. Toxicol Appl Pharmacol. (2014) 274:402–7.
doi: 10.1016/j.taap.2013.12.009
44. Campioli E, Martinez-Arguelles DB, Papadopoulos V. In utero exposure to the
endocrine disruptor di-(2-ethylhexyl) phthalate promotes local adipose and
systemic inflammation in adult male offspring. Nutr Diabetes (2014) 4:e115.
doi: 10.1038/nutd.2014.13
45. Vetrano AM, Laskin DL, Archer F, Syed K, Gray JP, Laskin JD, et al.
Inflammatory effects of phthalates in neonatal neutrophils. Pediatr Res. (2010)
68:134–9. doi: 10.1203/00006450-201011001-00260
46. Hadrup N, Svingen T, Mandrup K, Skov K, Pedersen M, Frederiksen H,
et al. Juvenile male rats exposed to a low-dose mixture of twenty-seven
environmental chemicals display adverse health effects. PLoS ONE (2016)
11:e0162027. doi: 10.1371/journal.pone.0162027
Frontiers in Public Health | www.frontiersin.org 11 October 2018 | Volume 6 | Article 298
Zhou et al. Metabolomic Markers of Phthalate Exposure
47. Romero-Franco M, Hernandez-Ramirez RU, Calafat AM, Cebrian ME,
Needham LL, Teitelbaum S, et al. Personal care product use and urinary levels
of phthalate metabolites in Mexican women. Environ Int. (2011) 37:867–71.
doi: 10.1016/j.envint.2011.02.014
48. Arbuckle TE, Davis K, Marro L, Fisher M, Legrand M, LeBlanc A,
et al. Phthalate and bisphenol A exposure among pregnant women in
Canada–results from the MIREC study. Environ Int. (2014) 68:55–65.
doi: 10.1016/j.envint.2014.02.010
49. Sathyanarayana S, Grady R, Barrett ES, Redmon B, Nguyen RH, Barthold JS,
et al. First trimester phthalate exposure and male newborn genital anomalies.
Environ Res. (2016) 151:777–82. doi: 10.1016/j.envres.2016.07.043
50. Ferguson KK, Loch-Caruso R, Meeker JD. Exploration of oxidative stress and
inflammatory markers in relation to urinary phthalate metabolites: NHANES
1999-2006. Environ Sci Technol. (2012) 46:477–85. doi: 10.1021/es20
2340b
51. Viola G, Meitto L, Secchi F, Ping L, Bruni A. Absorption and distribution of
arachidonate in rates receiving lysophospholipids by oral route. J Lipid Res.
(1993) 34:1843–52.
52. Bellini F, Viola G, Menegus A, Toffano G, A B. Signaling Mechanism in
the lysophosphatidylserine-induced activation of mouse mast cells. Biochem
Biophys Acta (1990) 1052:216–20
53. Muczynski V, Lecureuil C, Messiaen S, Guerquin MJ, N’Tumba-Byn T,
Moison D, et al. Cellular and molecular effect of MEHP Involving
LXRalpha in human fetal testis and ovary. PLoS ONE (2012) 7:e48266.
doi: 10.1371/journal.pone.0048266
54. Robinson JF, Verhoef A, van Beelen VA, Pennings JL, Piersma AH.
Dose-response analysis of phthalate effects on gene expression in
rat whole embryo culture. Toxicol Appl Pharmacol. (2012) 264:32–41.
doi: 10.1016/j.taap.2012.07.015
55. Jones S, Boisvert A, Naghi A, Hullin-Matsuda F, Greimel P, Kobayashi T, et al.
Stimulatory effects of combined endocrine disruptors on MA-10 Leydig cell
steroid production and lipid homeostasis. Toxicology (2016) 355–356:21–30.
doi: 10.1016/j.tox.2016.05.008
56. Russo SB, Ross JS, Cowart LA. Sphingolipids in obesity, type 2 diabetes,
and metabolic disease. Handb Exp Pharmacol. (2013) 216:373–401.
doi: 10.1007/978-3-7091-1511-4_19
57. Aburasayn H, Al Batran R, Ussher JR. Targeting ceramide metabolism
in obesity. Am J Physiol Endocrinol Metab. (2016) 311:E423–35.
doi: 10.1152/ajpendo.00133.2016
58. Gosejacob D, Jager PS, Vom Dorp K, Frejno M, Carstensen AC, Kohnke M,
et al. Ceramide synthase 5 is essential to maintain C16:0-ceramide pools and
contributes to the development of diet-induced obesity. J Biol Chem. (2016)
291:6989–7003. doi: 10.1074/jbc.M115.691212
59. Nikolova-Karakashian MN, Reid MB. Sphingolipid metabolism, oxidant
signaling, and contractile function of skeletal muscle. Antioxid Redox Signal.
(2011) 15:2501–17. doi: 10.1089/ars.2011.3940
60. Smith CA, Farmer K, Lee H, Holahan MR, Smith JC. Altered hippocampal
lipid profile following acute postnatal exposure to Di(2-Ethylhexyl)
phthalate in rats. Int J Environ Res Public Health (2015) 12:13542–59.
doi: 10.3390/ijerph121013542
61. Jo JY, Kim TH, Jeong HY, Lim SM, Kim HS, Im DS. Effect of Di-(2-
ethylhexyl)-phthalate on sphingolipid metabolic enzymes in rat liver. Toxicol
Res. (2011) 27:185–90. doi: 10.5487/tr.2011.27.3.185
62. Baker DH, Czarnecki-Maulden GL. Pharmacologic role of cysteine in
ameliorating or exacerbating mineral toxicities. J Nutr. (1987) 117:1003–10.
doi: 10.1093/jn/117.6.1003
63. GahlWA, Thoene JG, Schneider JA. Cystinosis.NEngl J Med. (2002) 347:111–
21. doi: 10.1056/NEJMra020552
64. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide,
a key NAD+ intermediate, treats the pathophysiology of diet-
and age-induced diabetes in mice. Cell Metab. (2011) 14:528–36.
doi: 10.1016/j.cmet.2011.08.014
65. IUPAC-IUB Commission on Biochemical Nomenclature. Nomenclature and
symbolism for amino acids and peptides (IUPAC-IUB Recommendations
1983). Pure Appl Chem. (1984) 56:595–624. doi: 10.1351/pac1984560
50595
66. Savchuk I, Soder O, Svechnikov K. Mono-2-ethylhexyl phthalate stimulates
androgen production but suppresses mitochondrial function in mouse leydig
cells with different steroidogenic potential. Toxicol Sci. (2015) 145:149–56.
doi: 10.1093/toxsci/kfv042
67. Edlund C, Ganning A, G D. The influence of prolonged di(2-
ethylhexyl)phthalate treatment on the dolichol and dolichyl-P content
of rate liver. Chem Biol Interact. (1986) 57:251–8.
68. Ganning A, Brunk U, Edlund C, Elhammer A, Dallner G. Effects of prolonged
administration of phthalate ester on the liver. Environ Health Perspect. (1987)
73:251–8.
69. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid
hormones in primate pregnancy. Endocr Rev. (1995) 16:608–48.
doi: 10.1210/edrv-16-5-608
70. Paitz RT, Bowden RM. Sulfonation of maternal steroids is a conserved
metabolic pathway in vertebrates. Integr Comp Biol. (2013) 53:895–901.
doi: 10.1093/icb/ict027
71. Martinez-Arguelles DB, Papadopoulos V. Prenatal phthalate exposure:
epigenetic changes leading to lifelong impact on steroid formation. Andrology
(2016) 4:573–84. doi: 10.1111/andr.12175
72. Sohn J, Kim S, Koschorreck J, Kho Y, Choi K. Alteration of sex
hormone levels and steroidogenic pathway by several low molecular weight
phthalates and their metabolites in male zebrafish (Danio rerio) and/or
human adrenal cell (H295R) line. J Hazard Mater. (2016) 320:45–54.
doi: 10.1016/j.jhazmat.2016.08.008
73. Solomon O, Yousefi P, Huen K, Gunier RB, Escudero-Fung M, Barcellos LF,
et al. Prenatal phthalate exposure and altered patterns of DNAmethylation in
cord blood. Environ Mol Mutagen. (2017) 58:398–410. doi: 10.1002/em.22095
74. Tindula G, Murphy SK, Grenier C, Huang Z, Huen K, Escudero-
Fung M, et al. DNA methylation of imprinted genes in
Mexican-American newborn children with prenatal phthalate
exposure. Epigenomics (2018) 10:1011–26. doi: 10.2217/epi-
2017-0178
75. Sureda A, Del Mar Bibiloni M, Martorell M, Buil-Cosiales P, Marti A, Pons A,
et al. Mediterranean diets supplemented with virgin olive oil and nuts enhance
plasmatic antioxidant capabilities and decrease xanthine oxidase activity in
people with metabolic syndrome: the PREDIMED study. Mol Nutr Food Res.
(2016) 60:2654–64. doi: 10.1002/mnfr.201600450
76. Liu J, Litt L, Segal MR, Kelly MJ, Pelton JG, Kim M. Metabolomics
of oxidative stress in recent studies of endogenous and exogenously
administered intermediate metabolites. Int J Mol Sci. (2011) 12:6469–501.
doi: 10.3390/ijms12106469
77. Ooga T, Sato H, Nagashima A, Sasaki K, Tomita M, Soga T, et al.
Metabolomic anatomy of an animal model revealing homeostatic imbalances
in dyslipidaemia.Mol Biosyst. (2011) 7:1217–23. doi: 10.1039/c0mb00141d
78. Liu J, Wang C, Liu F, Lu Y, Cheng J. Metabonomics revealed xanthine
oxidase-induced oxidative stress and inflammation in the pathogenesis
of diabetic nephropathy. Anal Bioanal Chem. (2015) 407:2569–79.
doi: 10.1007/s00216-015-8481-0
79. von Daniken A, Lutz WK, Jackh R, Schlatter C. Investigation of the potential
for binding of Di(2-ethylhexyl) phthalate (DEHP) and Di(2-ethylhexyl)
adipate (DEHA) to liver DNA in vivo. Toxicol Appl Pharmacol. (1984)
73:373–87.
80. Ala-KorpelaM, SmithGD.Metabolic profiling-multitude of technologies with
great research potential, but (when) will translation emerge? Int J Epidemiol.
(2016) 45:1311–8. doi: 10.1093/ije/dyw305
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The handling editor declared a past co-authorship with one of the authors
NH.
Copyright © 2018 Zhou, Ford, Lee, Tindula, Huen, Tran, Bradman, Gunier,
Eskenazi, Nomura and Holland. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Public Health | www.frontiersin.org 12 October 2018 | Volume 6 | Article 298
